INTRODUCTION

Glioblastoma (GBM) is the most common malignant primary brain tumor, accounting for nearly half of all adult primary brain cancer cases [1]. Unfortunately, the median survival (MS) of patients diagnosed with GBM is less than one year, while the 5-year overall survival (OS) rate is approximately 5%–10% [1]. Characteristically, there is a detrimental correlation between increasing age and survival in GBM, even though half of the affected patients are aged >65 years [1-5]. Furthermore, patients aged >70 years were not eligible for the landmark trial by Stupp et al. [6], which excluded elderly patients from possibly attaining the reported OS benefit of temozolomide (TMZ) in combination with radiotherapy (RT).

There are several inherent challenges regarding the treatment of elderly patients with GBM (GBM-e). Although GBM-e are fit enough to undergo standard TMZ-based radiochemotherapy, they do not do well as younger patients, with an MS of 9–14 months, and 16 months at most for highly selected patients [7-12]. Furthermore, older patients often present with worse performance status and multiple comorbidities than their younger counterparts. They are also vulnerable to treatment-related toxicities due to the fragility of aged brain tissues, which is very difficult to accurately evaluate before initiating treatment [13,14] and may ultimately lead to undertreatment of elderly patients, resulting in suboptimal outcomes [15,16].

Using the National Cancer Database (2004–2016), Nunna et al. [15] reported that there is twice the chance for GBM-e aged ≥65 years of not receiving surgery, RT, or chemotherapy. However, RT significantly prolonged OS in these elderly patients, even if they had a poor performance status or did not undergo surgical resection [15]. Finally, defining the cut-off age for ‘elderly’ individuals is a complicated process, as the life expectancy of individuals has increased over time [17].

In this review, current evidence regarding RT for GBM-e is summarized based on published literature. Furthermore, important issues that need to be addressed are also highlighted.
PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GBM

One of the major steps in treating patients with cancer is the precise measurement of expected prognosis and balancing the risk-to-benefit ratio of certain treatments, especially in patients who are expected to demonstrate limited survival, which is the case with GBM-e.

The reported prognostic factors for GBM-e did not differ from those reported for younger patients. The extent of resection stands as a major prognostic factor for GBM-e [12,18-21]. Supratotal (hazard ratio [HR] 0.65; *p*<0.001) and gross total resection (HR 0.61; *p*<0.0001) were shown to significantly lower the risk of death in GBM-e aged ≥65 years compared to biopsy or local excision, which was a consistent finding across all age groups, except for GBM-e aged ≥90 years, based on data from the Surveillance, Epidemiology, and End Results Program [18]. In a recent meta-analysis involving 13 retrospective studies, gross total resection significantly improved OS in GBM-e compared with subtotal resection (HR 0.70; *p*<0.001) [19]. Performance status also significantly affected OS in newly diagnosed GBM-e, as in younger patients [4,12,21]. Methylation of the O6-methylguanine-DNA methyltransferase (*MGMT*) promoter is a favorable prognostic factor that particularly predicts response to TMZ in GBM-e treated by either TMZ or TMZ-based radiochemotherapy [12,22-26], as reported by secondary analyses of randomized trials and retrospective series. In contrast, promoter methylation of the *MGMT* gene (*MGMT+*) does not appear to impact OS in GBM-e treated by RT alone [22-24]. The presence of lymphopenia has also recently become identified as an unfavorable prognostic factor [21,26].

It should be borne in mind that patients who have good prognostic factors and are expected to survive longer are not necessarily also those who would benefit from certain treatments. Although more aggressive and intense treatments may be considered for these patients, whether a specific subgroup benefits from the treatment is a different issue.

BIOLOGICAL ASPECTS OF STANDARD RADIOTHERAPY DOSE FOR PATIENTS WITH GBM

Estimation of the biologically effective dose (BED) of RT in tumor cells and normal tissue is based on the intrinsic radiosensitivity of the target tumor cells, which is briefly summarized as the ‘α/β ratio (Gy)’ according to a linear-quadratic dose-response model, in radiobiology [27]. The BED for GBM is calculated as follows: total dose × [1 + daily dose/(α/β ratio)]. GBM cells are estimated to have an α/β ratio of 8 Gy (range, 5.0–10.8 Gy) [28], which is higher than that of the normal tissues within the central nervous system (2 Gy). A BED of 60 Gy in 30 fractions and 40.05 Gy in 15 fractions was calculated as 75 Gy and 53.42 Gy using an α/β ratio of 8 Gy. Therefore, theoretically, the former RT regimen would result in superior GBM cell killing and tumor control. However, the BED in normal brain tissue was higher in the former regimen (120 Gy vs. 93.52 Gy). Theoretically, this would increase the risk of complications, such as radionecrosis or brain edema, especially in elderly patients with more fragile brain tissues.

For several decades, the optimal radiotherapy dose for high-grade gliomas has been established by two major studies [29, 30]. The Brain Tumor Study Group pooled 621 patients with malignant glioma from their protocols between 1966 and 1975 and reported a dose-survival relationship favoring 60 Gy over lower dose schemes or no RT [29]. Compared to no RT, ≤45 Gy and 50 Gy, patients treated with 60 Gy (6 weeks) demonstrated a significant absolute MS benefit of 24 weeks (*p*=0.001), 28.5 weeks (*p*=0.001), and 14 weeks (*p*=0.004), respectively. The Medical Research Council Brain Tumour Working Party performed a prospective randomized trial comparing 60 Gy in 6 weeks vs. 45 Gy in 4 weeks following surgery in grade 3–4 astrocytomas [30]. One-third of 474 patients were aged ≥60 years. Compared with patients treated with a lower dose of 45 Gy, an absolute survival benefit of 2 months was observed in patients treated with 60 Gy (*p*=0.04). Significant survival benefit of a higher RT dose was maintained even in patients with the poorest prognostic indicators, based on age, performance, extent of surgery, and history of fits [30]. Taken together, a standard RT dose of 60 Gy in 6 weeks has been established for high-grade gliomas and this has not changed for several decades [5,6,31-34].

RADIOTHERAPY ALONE FOLLOWING SURGERY IN ELDERLY PATIENTS WITH GBM

Major prospective randomized trials investigating RT alone are summarized in Table 1. The pivotal role of RT in GBM-e aged ≥70 years was defined in a prospective randomized study by Keime-Guibert et al. [35] from the Association des NeuroOncoloègues d’Expression Française. A conventionally fractionated RT (CFRT) regimen of 50 Gy (1.8 Gy per fraction) demonstrated an absolute MS benefit of 3 months compared with best supportive care (29 weeks vs. 17 weeks; *p*=0.002; HR for death, 0.47) following surgery in GBM-e. In this study, progression-free survival was also significantly prolonged in the RT arm, whereas performance status, health-related quality of life, and neurocognition did not differ significantly between the
Despite the significantly prolonged survival with RT, the necessity of an inconvenient and potentially morbid RT schedule of 6 weeks (60 Gy) has been questioned regarding its use in GBM-e since most GBM-e patients show very poor survival. Subsequently, efforts have been made to abbreviate the RT schedule in GBM-e. Roa et al. [36] prospectively compared a CFRT regimen of 60 Gy over 6 weeks with a hypofractionated RT (HFRT) schedule of 40 Gy in 15 fractions over 3 weeks in GBM-e aged ≥60 years. The median Karnofsky Performance Scale score was 70. In this trial, involving 50 patients in each arm, there was no difference in survival between the 60 Gy and 40 Gy groups (MS, 5.1 months vs. 5.6 months; p = 0.57). However, the proportion of patients requiring an increased dosage of post-RT corticosteroids was doubled in the CFRT arm compared to the HFRT arm (49% vs. 23%; p = 0.02) [36]. The Nordic Clinical Brain Tumour Study Group also performed a 3-arm prospective randomized trial comparing CFRT (60 Gy in 30 fractions) vs. HFRT (34 Gy in 10 fractions) vs. six cycles of TMZ alone in fairly performing GBM-e aged ≥60 years [24]. In this study, there was no difference in MS between GBM-e treated with 60 Gy and 34 Gy (p = 0.24). Notably, 34 Gy provided a longer MS than 60 Gy for patients aged ≥70 years (MS, 7.0 months vs. 5.2 months, p = 0.02). Furthermore, GBM-e patients treated with 6 cycles of TMZ alone demonstrated significantly prolonged survival compared to CFRT of 60 Gy (MS, 8.3 months vs. 6.0 months, p = 0.01), although this survival benefit was limited in MGMT+ patients [24].

Roa et al. [37] further abbreviated the RT schedule for elderly or frail GBM patients and compared two HFRT regimens of 40 Gy in 15 fractions over 3 weeks and 25 Gy in five fractions over 1 week in a trial by the International Atomic Energy Agency. Patients were eligible for this trial if they met either of the following criteria: 1) ≥50 years old with a KPS of 50–70; or 2) ≥65 years, KPS ≥50. Once again, there was no difference in MS between the two arms with an MS of 6.4 months and 7.9 months for patients treated with 40 Gy and 25 Gy, respectively (p = 0.988). Global health-related quality of life at 4 and 8 weeks post-RT was also similar between the two arms [37].

In the German NOA-08 trial for malignant astrocytomas, where approximately 90% were GBMs, Wick et al [22]. compared CFRT of 60 Gy over 6 weeks to TMZ alone following surgery in patients aged ≥65 years with KPS ≥60. There is no difference in survival between both arms, with an MS of 6.4 months and 7.9 months for CFRT and TMZ (pnon-inferiority = 0.033), respectively, indicating non-inferiority of TMZ alone. The median event-free survival likewise did not differ between both arms. MGMT promoter methylation is an indicator of the expected response to treatment. After a long-term follow-up of

---

**Table 1.** Prospective randomized trials assessing radiotherapy alone in elderly patients with newly diagnosed glioblastoma

| Study | Inclusion criteria | Arm 1 | Treatment | n | MS (mo) | Arm 2 | Treatment | n | MS (mo) | Arm 3 | Treatment | n | MS (mo) | P |
|-------|-------------------|-------|-----------|---|---------|-------|-----------|---|---------|-------|-----------|---|---------|---|
| Keime-Guibert et al. [35] | ≥70 years, KPS ≥70 | CFRT (50 Gy in 5–6 weeks) | 39 | 6.7 | Best supportive care | 42 | 3.9 | 0.002 |
| Roa et al. [36] | ≥60 years, KPS ≥50 | CFRT (60 Gy in 6 weeks) | 47 | 5.1 | HFRT (60 Gy in 3 weeks) | 48 | 5.6 | 0.570 |
| Roa et al. [37] | ≥50 years, KPS 50–70; ≥65 years, KPS ≥50 | HFRT (60 Gy in 3 weeks) | 50 | 6.4 | HFRT (25 Gy in 1 week) | 48 | 7.9 | 0.988 |
| Malmström et al. [24] | ≥60 years*, WHO performance score | ≥65 years, KPS ≥50 | 178 | 9.6 | TMZ | 195 | 8.6 | | |
| Wick et al. [22]† | ≥65 years since 2004; ≥90% of patients were glioblastoma | CFRT (60 Gy in 6 weeks) | 100 | 6.0 | HFRT (60 Gy in 2 weeks) | 64 | 7.5 | 0.24(CFRT vs. HFRT); 0.01(CFRT vs. TMZ) | |

*65 years since 2004; †90% of patients were glioblastoma. MS, median survival; KPS, Karnofsky Performance Scale; CFRT, conventionally fractionated radiotherapy; TMZ, temozolomide
7.5 years, MGMT+ patients treated with TMZ alone demonstrated the best MS (18.4 months) followed by MGMT+/MGMT- treated with CFRT (MS, 9.6/10.2 months), and then by MGMT- treated with TMZ (MS, 6.7 months) [23].

Taken together (Table 1), RT significantly improved MS in fairly performing GBM-e compared to best supportive care [34], and HFRT provided comparable outcomes to CFRT of 60 Gy when treated by RT alone [24,35,36], with higher convenience. When delivering HFRT, there is a consensus among experts that 40 Gy in 15 fractions over 3 weeks might be a better option because there is limited experience with the regimen of 25 Gy in five fractions in general, and the regimen would be more appropriate for relatively small tumors [38]. Furthermore, physicians should keep in mind that in GBM-e MGMT+ patients treated by adjuvant monotherapy following surgery TMZ alone is a reasonable option [22,23] (Table 1).

**TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY IN ELDERLY PATIENTS: PROSPECTIVE EVIDENCE**

Since the landmark trial published in 2005 by Stupp et al. [6], CFRT of 60 Gy plus concurrent and adjuvant TMZ (CFRT/TMZ→TMZ) has been the standard treatment for GBM patients aged <70 years, with a WHO performance status of 0–2. Although the overall survival benefit of TMZ was originally reported to be limited in MGMT+ patients [39], long-term follow-up revealed a significantly higher number of long-term survivors when TMZ was added to CFRT in MGMT- patients [40]. TMZ not only affects GBM tumor cell survival by itself but also functions as a well-acknowledged radiosensitizer by inhibiting RT-induced DNA double-strand break repair, eventually leading to increased mitotic catastrophe [41]. MGMT+ patients aged <70 years can also benefit further with the addition of lomustine to RT/TMZ→TMZ [42].

Continuous efforts to combine TMZ with various RT regimens for the treatment of GBM-e have been undertaken since 2005 (Table 2). Several prospective single-arm studies have reported superior MS results with RT/TMZ→TMZ in GBM-e [7-10] compared to the aforementioned prospective studies evaluating RT alone [22,24,35-37]. Minniti et al. [7] and Brandes et al. [8] have reported an MS of 10.6–13.7 months in GBM-e aged over 65–70 years treated with CFRT/TMZ→TMZ using 60 Gy in 30 fractions. Although neurotoxicity and mental status deterioration, which was mostly stabilized with steroids, were observed in a significant proportion of patients and direct comparison may not be appropriate, this CFRT/TMZ→TMZ regimen prolonged MS by 5–7 months compared to studies of RT alone [24,35-37]. Minniti et al. [9,10] also reported an MS of 9.3–12.4 months in GBM-e treated with HFRT/TMZ→

| Study                  | Design        | Inclusion criteria | Arm 1                  | Arm 2                  | p       | Note                                           |
|-----------------------|---------------|-------------------|------------------------|------------------------|---------|-----------------------------------------------|
| Minniti et al. [7]     | Phase 2, single-arm | ≥70 years, KPS ≥70 | CFRT + TMZ (60 Gy in 6 weeks) | 32 10.6 Neurotoxicity in 40%: mostly resolved with steroids |
| Brandes et al. [8]    | Phase 2, single-arm | ≥65 years, KPS ≥70 | CFRT + TMZ (60 Gy in 6 weeks) | 58 11.7 Grade 3–4 mental status deterioration in 25% |
| Minniti et al. [9]    | Phase 2, single-arm | ≥70 years, KPS ≥60 | HFRT + TMZ (30 Gy in 6 fractions over 2 weeks) | 43 9.3 Neurological deterioration in 16% mostly resolved with steroids |
| Minniti et al. [10]   | Phase 2, single-arm | ≥70 years, KPS ≥60 | HFRT + TMZ (30 Gy in 6 fractions over 2 weeks) | 71 12.4 |
| Perry et al. [11]     | Phase 3, randomized | >65 years, KPS ≥60 | ECOG 0–2 MGMT+ HFRT alone (40 Gy in 3 weeks) | 88 11.5 Slightly higher rate of hematologic adverse events with TMZ |
|                       |               |                   | MGMT- HFRT alone (40 Gy in 3 weeks) | 95 10.0 |
|                       |               |                   | MGMT- HFRT alone (40 Gy in 3 weeks) | 77 7.9 |
|                       |               |                   | MGMT- HFRT alone (40 Gy in 3 weeks) | 79 0.055 |

MS, median survival; KPS, Karnofsky Performance Scale; ECOG, Eastern Cooperative Oncology Group; CFRT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy; TMZ, temozolomide; MGMT, O6-methylguanine-DNA methyltransferase
TMZ using HFRT regimens of 30 Gy in six fractions and 40 Gy in three fractions in subsequent prospective single-arm studies.

Perry et al. [11] confirmed the survival benefit of TMZ combined with HFRT for GBM-e in a phase 3 prospective randomized trial. A total of 562 patients aged ≥65 years with a WHO performance status of 0–2 were randomized to either HFRT/TMZ followed by 12 cycles of TMZ or HFRT alone, using 40 Gy in 15 fractions over 3 weeks as the HFRT regimen. MS was significantly improved from 7.6 months to 9.3 months with the addition of TMZ (p<0.001), although a slightly higher rate of hematologic adverse events was observed in the TMZ arm. Median progression-free survival was significantly improved in the HFRT/TMZ→TMZ arm from 3.9 months to 5.3 months (p<0.001). As in younger patients [39], the benefit of adding TMZ was pronounced in MGMT+ GBM-e, with an absolute MS benefit of 6 months (7.7→13.5 months; p<0.001) [11]. Notably, although statistical significance was not reached, MGMT- GBM-e also demonstrated a modest but clinically meaningful MS improvement of 2 months with TMZ (7.9→10.0 months, p=0.055). Of note, the eligibility criteria of this trial stated that only patients "who were deemed by their physicians not to be suitable to receive CFRT (60 Gy in 30 fractions over 6 weeks) in combination with TMZ" were eligible. To date, there is no gold standard for deciding which RT regimen (CFRT vs. HFRT) would be appropriate in GBM-e patients with a WHO performance score of 0–2, and this is an issue that needs to be addressed urgently.

A small subgroup analysis (n=42) of GBM-e patients aged ≥70 years from the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO) reported a survival benefit of TMZ limited to MGMT+ patients when added to RT [43]. Notably, RT regimens varied among patients. In MGMT+ patients (n=17), the MS was 17.2 months and 8.8 months in the RT plus TMZ and RT alone groups, respectively. In contrast, for MGMT- patients (n=25), the MS for RT plus TMZ and RT alone groups were 8.5 months and 8.0 months, respectively [43]. Therefore, one can argue that, in GBM-e, TMZ should be used only for MGMT+ patients when combined with RT.

One randomized phase 3 trial is ongoing in Japan to confirm the non-inferiority of 25 Gy in five fractions compared to 40 Gy in 15 fractions in the context of RT/TMZ→TMZ for GBM-e aged ≥70 years [44]. A total of 270 patients with ECOG performance status of 0–3 are planned for accrual. Conversely, the Korean Radiation Oncology Group recently approved a multi-institutional phase 3 prospective randomized trial (unpublished; KROG 21-11, http://www.krog.or.kr/ing/bbs/board.php?bo_table=protocols&sqla) comparing 60 Gy in 30 fractions to 40 Gy in 15 fractions in GBM-e aged ≥70 years with a fair performance status of KPS ≥60. The stratification factors will include institution, performance status, methyla-

What is the most adequate RT dose fractionation for GBM-e that is deemed suitable for TMZ-based radiochemotherapy? Would an abbreviated course of HFRT fit all patients treated with TMZ? Several small- to large-scale retrospective studies have attempted to answer these questions [12,45–48].

A small retrospective series from Dana-Farber/Brigham and Women’s Cancer Center compared HFRT (n=34; 40 Gy in 15 fractions) and CFRT (n=57; 59.4 Gy in 33 fractions or 60 Gy in 30 fractions) in the setting of TMZ in GBM-e aged ≥65 years [45]. No difference in survival was observed with or without propensity score matching, although MS was slightly longer with CFRT plus TMZ (11.1 months vs. 9.6 months). In Italy, Navarra et al. [46] compared GBM-e patients aged 65–69 years who were treated with 60 Gy in 30 fractions with those aged ≥70 years who were treated with 40.5 Gy in 15 fractions. All the patients were treated with concurrent and adjuvant TMZ therapy. After propensity score matching, the MS for the 65- to 69-year group (n=86) and ≥70-year group (n=86) were 14 months and 12 months, respectively, without a statistical difference (p=0.357). Based on these results, the authors suggested that HFRT combined with TMZ should be considered even in younger elderly patients with GBM [46].

In contrast, Gzell et al. [47] reported a significant survival benefit of CFRT (60 Gy) over HFRT (40 Gy) in 48 GBM-e patients aged 65–75 years who were treated with RT combined with concurrent TMZ, concurrent plus adjuvant TMZ, or adjuvant TMZ (Table 3). The MS for patients receiving 40 Gy and 60 Gy were 11 and 15 months (p<0.0001), respectively. Using the National Cancer Database, Mak et al. [48] have also reported a significant MS benefit in GBM-e patients aged ≥70 years when treated with CFRT (58–63 Gy in 1.8–2.0 Gy fractions) compared to HFRT (34–42 Gy in 2.5–3.4 Gy fractions). Notably, although there is no high-level evidence supporting the superiority of CFRT over HFRT in GBM-e to date, 93.4% of the 4,598 patients received CFRT. With a median follow-up of 21.0 months for survivors, the MS for CFRT and HFRT were 8.9 months and 4.9 months (p<0.0001), respectively. Significance was confirmed using multivariate analysis. Furthermore, in patients (76.9%) who were treated with RT plus chemother-
Evidence-based practice guidelines for the treatment of GBM have been published by several groups. The European Association of Neuro-Oncology recommends HFRT alone for patients with MGMT-GBM-e aged ≥70 years, whereas TMZ-based radiochemotherapy or TMZ alone is recommended for those who are MGMT+ [31]. For patients with unfavorable prognostic factors, defined by age and/or performance, consideration of HFRT as the RT regimen is recommended. In the intergroup consensus review by the Society for Neuro-Oncology and European Society of Neuro-Oncology, if the patient is deemed able to tolerate multimodality therapy, RT/TMZ→TMZ ± tumor treating fields (TTF) with either CFRT or HFRT is recommended [5]. For patients not suitable for multimodality treatment, HFRT is recommended [5]. For patients with MGMT+ GBM-e, it should be noted that only elderly patients who were deemed suitable for TMZ-based chemoradiotherapy or TMZ alone showed a survival benefit of CFRT over HFRT (p<0.001). Since this study included patients treated with RT plus concurrent and adjuvant TMZ, more patients included in this study (p=0.002) compared to Hoffer et al. [31, 47, 48]. This multi-institutional study included 196 patients aged ≥65 years, and the MS was 17.6 months for the CFRT group and 13.2 months for the HFRT group (p<0.001). All patients were treated with RT plus concurrent and adjuvant TMZ; multivariate analysis confirmed the survival benefit of CFRT; CFRT was superior across all subgroups.

**SUMMARY OF CURRENT GUIDELINES**

Evidence-based practice guidelines for the treatment of GBM have been published by several groups. The European Association of Neuro-Oncology recommends HFRT alone for patients with MGMT-GBM-e aged ≥70 years, whereas TMZ-based radiochemotherapy or TMZ alone is recommended for those who are MGMT+ [31]. For patients with unfavorable prognostic factors, defined by age and/or performance, consideration of HFRT as the RT regimen is recommended. In the intergroup consensus review by the Society for Neuro-Oncology and European Society of Neuro-Oncology, if the patient is deemed able to tolerate multimodality therapy, RT/TMZ→TMZ ± tumor treating fields (TTF) with either CFRT or HFRT is recommended [5]. For patients not suitable for multimodality treatment, HFRT is recommended [5]. For patients with MGMT+ GBM-e, it should be noted that only elderly patients who were deemed suitable for TMZ-based chemoradiotherapy or TMZ alone showed a survival benefit of CFRT over HFRT (p<0.001). Since this study included patients treated with RT plus concurrent and adjuvant TMZ, more patients included in this study (p=0.002) compared to Hoffer et al. [31, 47, 48]. This multi-institutional study included 196 patients aged ≥65 years, and the MS was 17.6 months for the CFRT group and 13.2 months for the HFRT group (p<0.001). All patients were treated with RT plus concurrent and adjuvant TMZ; multivariate analysis confirmed the survival benefit of CFRT; CFRT was superior across all subgroups.

**Table 3. Selected retrospective studies demonstrating the benefit of conventionally fractionated radiotherapy compared to hypofractionated radiotherapy when combined with chemotherapy**

| Study          | Inclusion criteria | CFRT | HFRT |
|----------------|-------------------|------|------|
| Gzell et al. [47] | 65–75 years       | 60 Gy in 6 weeks TMZ | N/A | 15.0 | 40 Gy in 3 weeks TMZ | N/A | <0.001 | n=48 (all patients) |
| Mak et al. [48]  | ≥70 years          | 58–63 Gy in 1.8–2.0 Gy fractions | Detail N/A | 3,407 | 9.7 | 34–42 Gy in 2.5–3.4 Gy fractions | Detail N/A | 130 | 5.6 | <0.001 National Cancer Database |
| Wee et al. [12]  | ≥65 years          | 60 Gy in 6 weeks Concurrent and adjuvant TMZ | 196 | 17.6 | 45 Gy in 3 weeks Concurrent and adjuvant TMZ | 64 | 13.2 | <0.001 |
|                 | ≥70 years          | 60 Gy in 6 weeks Concurrent and adjuvant TMZ | 84 | 16.4 | 45 Gy in 3 weeks Concurrent and adjuvant TMZ | 50 | 13.3 | 0.002 |

**Note**

CFRT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy; MS, median survival; N/A, not available; TMZ, temozolomide.
aged ≥70 years, although the selection of a specific treatment strategy may be very difficult for physicians [33]. In patients with a KPS ≥60 and MGMT+ status, both HFRT/TMZ→TMZ and CFRT/TMZ→TMZ plus TTF are recommended as category 1. CFRT/TMZ→TMZ and TMZ alone can be considered as category 2A. HFRT alone can also be considered category 2B in these patients. For patients with KPS ≥60 and MGMT−, CFRT/TMZ→TMZ plus TTF is recommended as category 1, whereas three different options (CFRT/TMZ→TMZ, HFRT/TMZ→TMZ, and HFRT alone) can also be considered as category 2A. GBM-e patients with a KPS <60 can be treated with HFRT alone, TMZ alone, or best supportive care (all category 2A). Guidelines for newly diagnosed GBM-e from the Korean Society for Neuro-Oncology are similar to the National Comprehensive Cancer Network guidelines but include fewer treatment options because TTF is not available in Korea [32].

Although published in the pre-TMZ era for GBM-e, the American Society for Radiation Oncology guidelines made an emphatic statement in that "there is no evidence that CFRT (60 Gy in 30 fractions over 6 weeks) is more efficacious than HFRT (e.g., 40 Gy in 15 fractions over 3 weeks)" [34]. This expert panel also suggested that HFRT was more appropriate, even for GBM-e with good performance status.

GERIATRIC ASSESSMENT IN ELDERLY PATIENTS

“Old” does not necessarily mean “bad.” Chronological age and performance scores, which are routinely measured parameters in oncology practice, might not necessarily reflect the exact frailty of elderly patients with cancer in certain treatments. The American Society of Clinical Oncology recommends the routine use of geriatric assessment (GA) in cancer patients aged ≥65 years receiving chemotherapy to identify the vulnerabilities of individuals and that GA results should be integrated for individualized planning of treatment selection [49]. Multiple studies have shown that GA-based interventions and modification of dosages, in chemotherapy regimens for example, successfully reduce toxicity in elderly patients with solid tumors or lymphoma while retaining acceptable oncologic outcomes [50-53]. Comprehensive GA might be time-consuming; therefore, the selection of an optimal assessment tool requiring a shorter administration time might be necessary for daily clinical practice [49].

Frailty in patients with GBM-e aged ≥65 years, measured by the Canadian Study of Health and Aging modified frailty index, has also been reported to correlate with lesser resection, longer hospitalization, increased complication risk, and decreased survival [13]. The G-8 screening tool, derived from the Mini Nutritional Assessment, which only takes approximately five minutes, is known for its correlation with mortality, even when controlling for cancer stage and performance status. Deluche et al. [54] showed that G-8 scores correlated with survival in GBM-e aged ≥65 years, even after adjusting for age, resection, chemotherapy, and RT. Geriatric assessment using various screening tools might be one strategy to identify GBM-e patients who would benefit from a more intensified RT schedule of CFRT (6 weeks) over HFRT (3 weeks) when combined with TMZ.

RADIATION ONCOLOGIST’S PERSPECTIVE AND CONCLUSION

Since 70%–90% of GBM recurrences after RT are local recurrences in the primary RT field or around the tumor bed, there is an urgent need for strategies to enhance the efficacy of local RT in GBM. Two simple strategies include increasing the physical dose of RT and using novel RT radiosensitizers. The latter is also an interesting field under active investigation, which includes agents such as epidermal growth factor receptor inhibitors, DNA damage repair pathway inhibitors, antiangiogenic therapies, and histone deacetylase inhibitors [55,56]; however, this will not be further discussed in this review.

To date, brachytherapy, hypofractionation, accelerated hyperfractionation, and stereotactic radiotherapy boost have failed to significantly improve overall survival in GBM compared to CFRT of 60 Gy in a phase 3 prospective randomized trial. Although a recent meta-analysis revealed that dose-escalated RT demonstrated a survival benefit compared with standard RT of 60 Gy, the difference in survival diminished in patients treated with RT plus TMZ [57]. Furthermore, the multicenter phase 3 SPECTRO-GLIO trial comparing standard CFRT of 60 Gy (30 fractions) and simultaneous integrated boost of up to 72 Gy (30 fractions) for regions of high choline to N-acetyl aspartate ratios identified by magnetic resonance spectroscopy in GBM treated with RT/TMZ→TMZ was recently presented at the European Society Radiation Oncology 2021 Meeting [58, 59]. However, no difference in overall or progression-free survival was observed between both arms (MS, 22.6 months vs. 22.2 months; p=0.55). For GBM-e, a small retrospective study comparing two 3-week HFRT regimens of 40 Gy (n=39) vs. 52.5 Gy (dose-escalated arm, n=27) in GBM-e patients aged ≥60 years treated with HFRT/TMZ→TMZ was presented in the 2021 American Society for Radiation Oncology Annual Meeting [60]. MS was significantly prolonged with dose escalation in univariate and multivariate analyses. However, dose escalation in HFRT needs to be evaluated prospectively in the future. Currently, 40 Gy in 15 fractions should remain the standard HFRT regimen.

What should not be overlooked is the fact that a direct com-
comparison between TMZ alone and RT/TMZ→TMZ in MGMT+ GBM-e patients has not yet been performed. Since both regimens offered an improved MS of 18.4 months [23] and 13.5 months [11] in MGMT+ GBM-e individuals when compared to historical controls, we should keep in mind that TMZ alone is a reasonable treatment strategy in these patients. However, treatment with TMZ alone for newly diagnosed GBM is not reimbursed by the National Health Insurance in Korea, which warrants modification.

In summary, since TMZ prolongs survival in combination RT for GBM-e patients, the optimal RT dose-fractionation in GBM-e patients suitable for RT/TMZ→TMZ needs to be addressed urgently in the near future. Furthermore, a single RT schedule, either CFRT or HFRT, would probably not fit all GBM-e; therefore, methods for appropriate patient selection based on the risk-benefits of CFRT and HFRT in combination with TMZ need to be established. We also should not be confused that GBM-e patients harboring favorable prognosticators, such as MGMT+ or gross total resection, do not qualify as the best candidates for a longer course of CFRT rather than abbreviated HFRT. The results, as well as the detailed data of subgroup analyses of ongoing prospective phase 3 trials comparing 40 Gy (3 weeks) to 25 Gy (1 week) and 60 Gy (6 weeks) in the context of TMZ-based radiochemotherapy for GBM-e, are eagerly awaited.

**Ethics Statement**

Not applicable

**Availability of Data and Material**

Data sharing not applicable to this article as no datasets were generated or analyzed during the study.

**ORCID iD**

Chan Woo Wee [https://orcid.org/0000-0002-0631-7549](https://orcid.org/0000-0002-0631-7549)

**Conflicts of Interest**

The author has no potential conflicts of interest to disclose.

**Funding Statement**

None

**REFERENCES**

1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol 2021;23(12 Suppl 2):ii1-105.
2. Ogahki H, Dessen P, Joure B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9.
3. Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, et al. Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma. Clin Cancer Res 2020;26:5232-45.
4. Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, et al. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol 2017;123:106-11.
5. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073-113.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
7. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008;88:97-103.
8. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009;115:3512-8.
9. Minniti G, De Sanctis V, Muni R, Rasio D, Lanzetta G, Bozzao A, et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 2009;91:95-100.
10. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012;83:93-9.
11. Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017;376:1027-37.
12. Wee CW, Kim IH, Park CK, Kim N, Suh CO, Chang JH, et al. Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection? J Neurooncol 2020;148:57-65.
13. Cloney M, D’Amico R, Lebovic J, Nazarian M, Zacharia BE, Sisti MB, et al. Frailty in geriatric glioblastoma patients: a predictor of operative morbidity and outcome. World Neurosurg 2016;89:362-7.
14. Gavrilovic TT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570-4.
15. Nunna RS, Khalid SI, Patel S, Sethi A, Behbahani M, Mehta AI, et al. Outcomes and patterns of care in elderly patients with glioblastoma multiforme. World Neurosurg 2021;149:e1026-37.
16. Koh HK, Kim H, Hong S. Patterns of care after surgery for elderly patients with malignant brain tumors: data from the National Health Insurance Service in South Korea. Anticancer Res 2019;39:5733-9.
17. Global health estimates: life expectancy and healthy life expectancy. Geneva: WHO, 2020. (Accessed November 23, 2021, at https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy.)
18. Lopez-Rivera V, Dono A, Lewis CT, Chandra A, Abdelkhaleq R, Sheth SA, et al. Extent of resection and survival outcomes of geriatric patients with glioblastoma: is there benefit from aggressive surgery? Clin Neurol Neurosurg 2019;200:1067.
19. Han Q, Liang H, Cheng P, Yang H, Zhao P. Gross total vs. subtotal resection on survival outcomes in elderly patients with high-grade glioma: a systematic review and meta-analysis. Front Oncol 2020;10:151.
20. Straube C, Kessel KA, Antoni S, Gempt J, Meyer B, Schlegel J, et al. A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. Radiat Oncol 2020;15:97.
21. Song AJ, Ding K, Alnahhas I, Laperriere NJ, Perry J, Mason WP, et al. Impact of lymphopenia on survival for elderly patients with glioblastoma: a secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial. Neurooncol Adv 2021;3:vdab153.
22. Wick W, Flatten M, Meinsner C, Felsberg J, Tabatabai G, Simon M, et al.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-15.

23. Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncol 2020;22:1162-72.

24. Malmström A, Gromberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-26.

25. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012;131:1342-50.

26. Kleinberg L, Sloan L, Grossman S, Lim M. Radiotherapy, lymphopenia, and host immune capacity in glioblastoma: a potentially actional toxicity associated with reduced efficacy of radiotherapy. Neurosurgery 2019;85:441-53.

27. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol 2018;64:19T7R01.

28. Pedicini P, Fiorentino A, Simeon V, Tinì P, Chiumento C, Pirtoli L, et al. Clinical radiochemistry of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol 2014;190:925-32.

29. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.

30. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991;64:769-74.

31. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti C, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170-86.

32. Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, et al. The Korean Society for Neuro-Oncology (KNSO) guideline for glioblastomas: version 2018.01. Brain Tumor Res Treat 2019;7:1-9.

33. NCCN guidelines: central nervous system cancers version 2.2021. N Engl J Med 2021;384:1192-200.

34.数学ML, Sloan L, Grossman S, Lim M. Radiotherapy, lymphopenia, and host immune capacity in glioblastoma: a potentially actional toxicity associated with reduced efficacy of radiotherapy. Neurosurgery 2019;85:441-53.

35. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol 2018;64:19T7R01.

36. Pedicini P, Fiorentino A, Simeon V, Tinì P, Chiumento C, Pirtoli L, et al. Clinical radiochemistry of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol 2014;190:925-32.

37. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.

38. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol 2018;64:19T7R01.

39. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol 2018;64:19T7R01.

40. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.

41. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylation agent temozolomide. Clin Cancer Res 2008;14:931-8.

42. Herrlinger U, Tzalis D, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CpGmG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019;393:678-88.

43. Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, et al. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol 2016;128:157-62.

44. Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, Mizusawa J, et al. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma: Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC Cancer 2021;21:1105.

45. Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 2015;92:384-9.

46. Navarria P, Pessina F, Franceschi C, Loi M, Bellu L, Clerici E, et al. The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. Radiother Oncol 2021;156:49-55.

47. Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Elderly patients aged 65-70 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide. J Neurooncol 2014;119:187-96.

48. Mak KS, Agarwal A, Qureshi MM, Truong MT. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med 2017;6:1192-200.

49. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnera- bilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 2018;36:2326-47.

50. Flammery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding treatment tolerability in older adults with cancer. J Clin Oncol 2021;39:2150-63.

51. Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnussen A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021;398:1894-904.

52. Spina M, Balzarotti M, Uziel L, Ferrari AJ, Fratino L, Magagnoli M, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838-46.

53. Corre R, Greillier L, Le Caër H, Audigier-Valette C, Baize N, Bérard H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021;398:1894-904.

54. Flammery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding treatment tolerability in older adults with cancer. J Clin Oncol 2021;39:2150-63.

55. Mathen P, Rowe L, Mackey M, Smart D, Tofilon P, Camphausen K. Use of a comprehensive geriatric assessment for the management of the G-8 geriatric screening tool in older patients with glioblastoma. Neurooncol Adv 2021;3:vdab015.

56. Delucche E, Leobon S, Lamarche E, Tubiana-Mathieu N. First validation of the G-8 geriatric screening tool in older patients with glioblastoma. J Geriatr Oncol 2019;10:159-63.

57. Mathen P, Rowe L, Mackey M, Smart D, Tofilon P, Camphausen K. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma: the Nordic randomised, phase 3 trial. Neuro Oncol 2016;18:547-56.

58. Mathen P, Rowe L, Mackey M, Smart D, Tofilon P, Camphausen K. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma: the Nordic randomised, phase 3 trial. Neuro Oncol 2016;18:547-56.
et al. Dose escalated radiation therapy for glioblastoma multiforme: an international systematic review and meta-analysis of 22 prospective trials. Int J Radiat Oncol Biol Phys 2021;111:371-84.

58. Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, et al. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer 2019;19:167.

59. Laprie A, Noel G, Chaltiel I, Truc G, Sunyach MP, Charissoux M, et al. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial. Radiother Oncol 2021;161 Suppl 1: S246-7.

60. Perlow HK, Yang M, Klamer B, Raval R, Blakaj DM, Arnett ALH, et al. Hypofractionated dose-escalation for elderly patients with a newly diagnosed glioblastoma improves survival. Int J Radiat Oncol Biol Phys 2021;111(3 Suppl):e597-8.